KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Gross Margin (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Gross Margin for 18 consecutive years, with 91.79% as the latest value for Q1 2026.

  • For Q1 2026, Gross Margin fell 165.0% year-over-year to 91.79%; the TTM value through Mar 2026 reached 93.63%, up 81.0%, while the annual FY2025 figure was 93.31%, 96.0% up from the prior year.
  • Gross Margin hit 91.79% in Q1 2026 for Regeneron Pharmaceuticals, down from 96.45% in the prior quarter.
  • Across five years, Gross Margin topped out at 96.45% in Q4 2025 and bottomed at 314.6% in Q1 2022.
  • Average Gross Margin over 5 years is 55.79%, with a median of 93.44% recorded in 2025.
  • On a YoY basis, Gross Margin climbed as much as 43802bps in 2022 and fell as far as -40736bps in 2022.
  • Regeneron Pharmaceuticals' Gross Margin stood at 138.4% in 2022, then surged by 168bps to 93.88% in 2023, then fell by -3bps to 91.38% in 2024, then increased by 6bps to 96.45% in 2025, then dropped by -5bps to 91.79% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods came in at 91.79%, 96.45%, and 93.59% for Q1 2026, Q4 2025, and Q3 2025 respectively.